Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 6/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MGMT | P16455 | 1/20 | 0.35 |
| ▸ | PDE9A | O76083 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.34 |
| ▸ | MPO | P05164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3441222 | 0.87 | ALDH1A1 (0.46) | TLR7ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL3441040 | 0.78 | TLR7 (0.39) | TLR7ADORA2ADHFRADORA1ADORA2B | |
| SCHEMBL3441092 | 0.73 | TLR7 (0.43) | TLR7ADORA2ADHFRADORA1ADORA3 | |
| SCHEMBL5410118 | 0.71 | TLR7 (0.45) | TLR7ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL3441043 | 0.71 | HSP90AA1 (0.50) | TLR7ADORA2AADORA1ADORA2BALDH1A1 | |
| SCHEMBL3441218 | 0.70 | HSP90AA1 (0.49) | TLR7ADORA2AADORA1ADORA2BALDH1A1 | |
| SCHEMBL5438145 | 0.70 | TLR7 (0.44) | TLR7ADORA2A | |
| SCHEMBL5398282 | 0.69 | ADORA2A (0.43) | TLR7ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL3441007 | 0.69 | FBP1 (0.50) | TLR7ADORA2ADHFRADORA1ADORA2B | |
| SCHEMBL3441461 | 0.68 | CYP2D6 (0.43) | TLR7ADORA2ADHFRADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7238700-B2 | A2B adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| EP-1401837-B1 | PURINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS INC (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20040209899-A1 | A2B adenosine receptor antagonists | PALLE VENKATA (IN) | 2004-10-21 | — | — | US | disclosed |
| EP-1401837-A1 | PURINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2004-03-31 | — | — | EP | disclosed |
| WO-2003006465-A1 | PARTIAL AND FULL AGONIST OF A ADENOSINE RECEPTORS | CV THERAPEUTICS, INC. (US) | 2003-01-23 | — | — | WO | disclosed |
| WO-2003002566-A1 | PURINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209899-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | TLR7 854/4885ADORA2A 2/4885DHFR 3072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.